Click Here for 5% Off Your First Aladdin Purchase!

LUT014 - 97%, high purity , CAS No.2274819-46-2, Inhibitor of B-Raf proto-oncogene; serine/threonine kinase

  • Moligand™
  • ≥97%
Item Number
L412553
Grouped product items
SKUSizeAvailabilityPrice Qty
L412553-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$39.90
L412553-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,241.90
L412553-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$59.90
L412553-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$589.90
L412553-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$939.90
View related series
MAPK/ERK Pathway

Basic Description

SynonymsLUT014|2274819-46-2|LUT-014|N5-(3-(7H-Purin-6-yl)pyridin-2-yl)-6-methyl-N1-(3-(trifluoromethoxy)phenyl)isoquinoline-1,5-diamine|T4E4I523RY|6-methyl-5-N-[3-(7H-purin-6-yl)pyridin-2-yl]-1-N-[3-(trifluoromethoxy)phenyl]isoquinoline-1,5-diamine|1,5-Isoquinoli
Specifications & Purity≥97%
Biochemical and Physiological MechanismsLUT014 is an inhibitor of B-Raf with IC50 of 11.7 nM, and reduces dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.
Storage TempProtected from light,Store at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of B-Raf proto-oncogene; serine/threonine kinase
Product Description

Information

LUT014 is an inhibitor of B-Raf with IC50 of 11.7 nM, and reduces dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.

Associated Targets

BRAF Tclin Serine/threonine-protein kinase B-raf 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 6-methyl-5-N-[3-(7H-purin-6-yl)pyridin-2-yl]-1-N-[3-(trifluoromethoxy)phenyl]isoquinoline-1,5-diamine
INCHI InChI=1S/C27H19F3N8O/c1-15-7-8-19-18(9-11-32-24(19)37-16-4-2-5-17(12-16)39-27(28,29)30)21(15)38-25-20(6-3-10-31-25)22-23-26(35-13-33-22)36-14-34-23/h2-14H,1H3,(H,31,38)(H,32,37)(H,33,34,35,36)
InChi Key FZPYULHBUBXPIG-UHFFFAOYSA-N
Canonical SMILES CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=CC=C3)OC(F)(F)F)NC4=C(C=CC=N4)C5=C6C(=NC=N5)N=CN6
Isomeric SMILES CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=CC=C3)OC(F)(F)F)NC4=C(C=CC=N4)C5=C6C(=NC=N5)N=CN6
PubChem CID 138319775
Molecular Weight 528.49

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

SensitivityLight sensitive

Related Documents

Alternative Products

References

1. Li T, Perez-Soler R.  (2009)  Skin toxicities associated with epidermal growth factor receptor inhibitors..  Target Oncol,  (2): (107-19).  [PMID:19452131]
2. Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A.  (2021)  Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy..  Cancer Discov,  129  (3): (589-97).  [PMID:33910927]

Solution Calculators